Impact of Tacrolimus Trough Variability on Acute Rejection Following Lung Transplantation.

Background: Acute rejection is a risk factor for the development of chronic lung allograft dysfunction, the leading cause of morbidity and mortality in lung transplant recipients. Calcineurin inhibitors are the cornerstone of immunosuppression regimens after lung transplantation.

Methods: We retrospectively evaluated the association of tacrolimus level variability with total acute rejection score at 12 months post-transplant.

Lung Transplantation and the Era of the Sensitized Patient.

Long term outcomes in lung transplant are limited by the development of chronic lung allograft dysfunction (CLAD). Within the past several decades, antibody-mediated rejection (AMR) has been recognized as a risk factor for CLAD. The presence of HLA antibodies in lung transplant candidates, "sensitized patients" may predispose patients to AMR, CLAD, and higher mortality after transplant.

Tacrolimus dose requirements in African-American and Caucasian kidney transplant recipients on mycophenolate and prednisone.

Racial differences among kidney transplant recipients may impact the total daily tacrolimus dose required to achieve therapeutic tacrolimus concentrations. Previous studies suggest that African Americans require higher doses to achieve similar therapeutic drug concentrations compared with Caucasians. Data were collected on a total of 147 de novo kidney transplant recipients.